Corton Capital Inc. Immunovant, Inc. Transaction History

Corton Capital Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $273,247 - $395,292	9,027 New	9,027 $291,000
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $139,217 - $299,899	7,505 New	7,505 $288,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $67,106 - $112,175	-19,854 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $79,791 - $138,294	-15,769 Reduced 44.27%	19,854 $109,000
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $261,116 - $332,006	35,623 New	35,623 $304,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.